Inovio Pharmaceuticals, Inc. (NASDAQ:INO)‘s stock had its “buy” rating reissued by equities researchers at Maxim Group in a report released on Tuesday. They presently have a $12.00 price target on the biopharmaceutical company’s stock. Maxim Group’s price target points to a potential upside of 102.70% from the company’s current price.

INO has been the subject of several other reports. Citigroup Inc. began coverage on Inovio Pharmaceuticals in a report on Wednesday, September 6th. They issued a “buy” rating and a $10.00 target price for the company. Zacks Investment Research upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Monday, May 15th. HC Wainwright set a $13.00 target price on Inovio Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, July 7th. Aegis upped their target price on Inovio Pharmaceuticals from $11.00 to $14.00 and gave the stock a “buy” rating in a report on Thursday, May 25th. Finally, ValuEngine upgraded Inovio Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 11th. One research analyst has rated the stock with a sell rating, three have given a hold rating and nine have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $19.80.

Inovio Pharmaceuticals (NASDAQ INO) opened at 5.92 on Tuesday. The stock’s market cap is $534.14 million. The firm’s 50-day moving average price is $5.69 and its 200 day moving average price is $6.69. Inovio Pharmaceuticals has a 12 month low of $5.28 and a 12 month high of $9.86.

Inovio Pharmaceuticals (NASDAQ:INO) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.21) by $0.08. Inovio Pharmaceuticals had a negative return on equity of 63.67% and a negative net margin of 153.46%. The business had revenue of $20.41 million during the quarter, compared to analysts’ expectations of $16.29 million. During the same period in the prior year, the business earned ($0.26) EPS. The business’s revenue for the quarter was up 229.2% compared to the same quarter last year. On average, analysts anticipate that Inovio Pharmaceuticals will post ($0.92) earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “Inovio Pharmaceuticals, Inc. (INO) Rating Reiterated by Maxim Group” was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another domain, it was stolen and reposted in violation of United States & international copyright and trademark legislation. The original version of this piece can be accessed at https://www.dailypolitical.com/2017/09/14/inovio-pharmaceuticals-inc-ino-rating-reiterated-by-maxim-group.html.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. Vanguard Group Inc. lifted its stake in shares of Inovio Pharmaceuticals by 4.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,227,219 shares of the biopharmaceutical company’s stock worth $25,301,000 after purchasing an additional 129,164 shares during the last quarter. Wasatch Advisors Inc. lifted its stake in shares of Inovio Pharmaceuticals by 43.6% during the 2nd quarter. Wasatch Advisors Inc. now owns 2,610,818 shares of the biopharmaceutical company’s stock worth $20,469,000 after purchasing an additional 793,306 shares during the last quarter. Northern Trust Corp lifted its stake in shares of Inovio Pharmaceuticals by 2.8% during the 2nd quarter. Northern Trust Corp now owns 896,472 shares of the biopharmaceutical company’s stock worth $7,028,000 after purchasing an additional 24,366 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Inovio Pharmaceuticals by 12.5% during the 1st quarter. Geode Capital Management LLC now owns 560,164 shares of the biopharmaceutical company’s stock worth $3,708,000 after purchasing an additional 62,045 shares during the last quarter. Finally, Bank of New York Mellon Corp lifted its stake in shares of Inovio Pharmaceuticals by 3.6% during the 1st quarter. Bank of New York Mellon Corp now owns 342,348 shares of the biopharmaceutical company’s stock worth $2,266,000 after purchasing an additional 11,765 shares during the last quarter. Hedge funds and other institutional investors own 24.83% of the company’s stock.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals, Inc (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases.

Analyst Recommendations for Inovio Pharmaceuticals (NASDAQ:INO)

Receive News & Ratings for Inovio Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inovio Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.